RespireRx Pharmaceuticals Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2010 to 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
RespireRx Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2022.
  • RespireRx Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2023 was -$396K, a 16.3% increase year-over-year.
  • RespireRx Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2023 was -$1.8M, a 30.6% increase year-over-year.
  • RespireRx Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$2.1M, a 33.1% increase from 2021.
  • RespireRx Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$3.14M, a 26.9% increase from 2020.
  • RespireRx Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$4.3M, a 103% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.